FI20075278A0 - Novel completely human anti-VAP-1 monoclonal antibodies - Google Patents
Novel completely human anti-VAP-1 monoclonal antibodiesInfo
- Publication number
- FI20075278A0 FI20075278A0 FI20075278A FI20075278A FI20075278A0 FI 20075278 A0 FI20075278 A0 FI 20075278A0 FI 20075278 A FI20075278 A FI 20075278A FI 20075278 A FI20075278 A FI 20075278A FI 20075278 A0 FI20075278 A0 FI 20075278A0
- Authority
- FI
- Finland
- Prior art keywords
- vap
- monoclonal antibodies
- human anti
- completely human
- novel completely
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Priority Applications (38)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20075278A FI20075278A0 (en) | 2007-04-20 | 2007-04-20 | Novel completely human anti-VAP-1 monoclonal antibodies |
RU2009142808/10A RU2459832C2 (en) | 2007-04-20 | 2008-04-17 | New completely human vap-1 monoclonal antibodies |
CA2683079A CA2683079C (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
CA3059571A CA3059571C (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
AU2008240560A AU2008240560B2 (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-VAP-1 monoclonal antibodies |
CA2962519A CA2962519C (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
RS20150427A RS54066B1 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibodies |
NZ580194A NZ580194A (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
CA3059580A CA3059580C (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
EP08736848.6A EP2164872B1 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibodies |
PCT/FI2008/050199 WO2008129124A1 (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
KR1020097021869A KR101352416B1 (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-VAP-1 monoclonal antibodies |
CN2008800209043A CN101679523B (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
PL08736848T PL2164872T3 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibodies |
LTEP13190488.0T LT2692737T (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
DK08736848.6T DK2164872T3 (en) | 2007-04-20 | 2008-04-17 | COMPLETE human anti-VAP-1 MONOCLONAL ANTIBODIES |
SI200831444T SI2164872T1 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibodies |
UAA200910613A UA97516C2 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibody |
EP13190488.0A EP2692737B1 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
HUE13190488A HUE041656T2 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
PT13190488T PT2692737T (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibodies |
DK13190488.0T DK2692737T3 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
ES13190488.0T ES2690307T3 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
SI200832000T SI2692737T1 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
ES08736848.6T ES2540566T3 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
CA3059600A CA3059600C (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
PL13190488T PL2692737T3 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 monoclonal antibodies |
JP2010503537A JP5728225B2 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-VAP-1 antibody, VAP-1 binding fragment, nucleic acid molecule, expression vector, host cell, and pharmaceutical composition |
PT87368486T PT2164872E (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibodies |
US12/081,707 US7897149B2 (en) | 2007-04-20 | 2008-04-18 | Fully human anti-VAP-1 monoclonal antibodies |
ZA200907220A ZA200907220B (en) | 2007-04-20 | 2009-10-15 | Novel fully human anti-VAP-1 monoclonal antibodies |
IL201601A IL201601A (en) | 2007-04-20 | 2009-10-18 | Fully human anti-vap-1 monoclonal antibodies |
HK10107584.5A HK1141039A1 (en) | 2007-04-20 | 2010-08-09 | Fully human anti-vap-1 monoclonal antibodies vap-1 |
US12/940,476 US8142783B2 (en) | 2007-04-20 | 2010-11-05 | Methods of treating an inflammatory condition involving VAP-1-mediated adhesion with VAP-1-specific antibodies |
HRP20150615TT HRP20150615T1 (en) | 2007-04-20 | 2015-06-08 | Fully human anti-vap-1 monoclonal antibodies |
CY20151100533T CY1116413T1 (en) | 2007-04-20 | 2015-06-23 | ANNOUNCED FULLY-HUMAN MONOCLONIC ANTI-VAP-1 |
CY181101032T CY1121132T1 (en) | 2007-04-20 | 2018-10-05 | FULLY-HUMAN MONOCLONE ANTIBODIES ANTI-vap-1 |
HRP20181616TT HRP20181616T1 (en) | 2007-04-20 | 2018-10-05 | Fully human anti-vap-1 monoclonal antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20075278A FI20075278A0 (en) | 2007-04-20 | 2007-04-20 | Novel completely human anti-VAP-1 monoclonal antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
FI20075278A0 true FI20075278A0 (en) | 2007-04-20 |
Family
ID=38009931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20075278A FI20075278A0 (en) | 2007-04-20 | 2007-04-20 | Novel completely human anti-VAP-1 monoclonal antibodies |
Country Status (25)
Country | Link |
---|---|
US (2) | US7897149B2 (en) |
EP (2) | EP2164872B1 (en) |
JP (1) | JP5728225B2 (en) |
KR (1) | KR101352416B1 (en) |
CN (1) | CN101679523B (en) |
AU (1) | AU2008240560B2 (en) |
CA (5) | CA3059600C (en) |
CY (2) | CY1116413T1 (en) |
DK (2) | DK2692737T3 (en) |
ES (2) | ES2690307T3 (en) |
FI (1) | FI20075278A0 (en) |
HK (1) | HK1141039A1 (en) |
HR (2) | HRP20150615T1 (en) |
HU (1) | HUE041656T2 (en) |
IL (1) | IL201601A (en) |
LT (1) | LT2692737T (en) |
NZ (1) | NZ580194A (en) |
PL (2) | PL2164872T3 (en) |
PT (2) | PT2164872E (en) |
RS (1) | RS54066B1 (en) |
RU (1) | RU2459832C2 (en) |
SI (2) | SI2692737T1 (en) |
UA (1) | UA97516C2 (en) |
WO (1) | WO2008129124A1 (en) |
ZA (1) | ZA200907220B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20075278A0 (en) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Novel completely human anti-VAP-1 monoclonal antibodies |
CN102459338A (en) * | 2009-05-08 | 2012-05-16 | 霍夫曼-拉罗奇有限公司 | Humanized anti-egfl7 antibodies and methods using same |
UA112154C2 (en) * | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Use of vap-1 inhibitors for treating fibrotic conditions |
TWI594764B (en) * | 2010-04-12 | 2017-08-11 | 生化治療公司 | Therapeutic use |
ES2702246T3 (en) * | 2012-03-26 | 2019-02-28 | Sanofi Sa | Stable IgG4 binding agent formulations |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
PL3387898T3 (en) * | 2013-03-15 | 2020-10-19 | Mayo Foundation For Medical Education And Research | Identification and monitoring of monoclonal immunoglobulins by molecular mass |
AU2014279863A1 (en) | 2013-06-12 | 2016-01-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
BR112016023046A8 (en) | 2014-04-04 | 2021-05-11 | Mayo Found Medical Education & Res | kit comprising antibodies and reducing agents |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
US10690676B2 (en) | 2014-07-29 | 2020-06-23 | Mayo Roundation for Medical Education and Research | Quantifying monoclonal antibody therapeutics by LC-MS/MS |
CN104628853B (en) * | 2015-02-06 | 2017-10-10 | 中国人民解放军南京军区军事医学研究所 | The anti-anthrax protective antigen PA in people source IgG antibody and its application |
US11209439B2 (en) | 2015-09-24 | 2021-12-28 | Mayo Foundation For Medical Education And Research | Identification of immunoglobulin free light chains by mass spectrometry |
AU2016366635A1 (en) | 2015-12-07 | 2018-06-21 | Benevolentai Cambridge Limited | VAP-1 inhibitors for treating pain |
US11161902B2 (en) | 2016-05-09 | 2021-11-02 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Tissue-specific exosomes as biomarkers |
US10955420B2 (en) | 2016-09-07 | 2021-03-23 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
EP3618865A4 (en) * | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
EP3681528A4 (en) | 2017-09-13 | 2021-07-21 | Mayo Foundation for Medical Education and Research | Identification and monitoring of apoptosis inhibitor of macrophage |
SG11202003479TA (en) * | 2017-10-18 | 2020-05-28 | Regenxbio Inc | Fully-human post-translationally modified antibody therapeutics |
CN111537740B (en) * | 2020-05-22 | 2021-11-23 | 长春生物制品研究所有限责任公司 | Forest encephalitis virus IgM antibody detection kit and application thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
US5580780A (en) | 1992-06-09 | 1996-12-03 | Jalkanen; Sirpa | Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies |
NZ299958A (en) * | 1992-06-09 | 2000-07-28 | Marko Salmi | Antagonising endothelial vascular adhesion protein-1 (VAP-1) mediated binding of endothelial cells to lymphocytes using anti-VAP-1-antibodiess |
JPH08509612A (en) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | Transgenic non-human animal capable of producing heterologous antibody |
WO1998053049A1 (en) * | 1997-05-23 | 1998-11-26 | Biotie Therapies Ltd. | Vascular adhesion protein-1 having amine oxidase activity |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
CA2481334A1 (en) * | 2002-04-01 | 2003-10-16 | Anthony C. Stevens | Tissue-specific endothelial membrane proteins |
FI20020807A0 (en) * | 2002-04-29 | 2002-04-29 | Biotie Therapies Oyj | Novel humanized anti-VAP-1 monoclonal antibodies |
FI20075278A0 (en) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Novel completely human anti-VAP-1 monoclonal antibodies |
-
2007
- 2007-04-20 FI FI20075278A patent/FI20075278A0/en unknown
-
2008
- 2008-04-17 CA CA3059600A patent/CA3059600C/en active Active
- 2008-04-17 DK DK13190488.0T patent/DK2692737T3/en active
- 2008-04-17 CA CA2683079A patent/CA2683079C/en active Active
- 2008-04-17 RU RU2009142808/10A patent/RU2459832C2/en active
- 2008-04-17 DK DK08736848.6T patent/DK2164872T3/en active
- 2008-04-17 WO PCT/FI2008/050199 patent/WO2008129124A1/en active Application Filing
- 2008-04-17 PT PT87368486T patent/PT2164872E/en unknown
- 2008-04-17 JP JP2010503537A patent/JP5728225B2/en not_active Expired - Fee Related
- 2008-04-17 SI SI200832000T patent/SI2692737T1/en unknown
- 2008-04-17 ES ES13190488.0T patent/ES2690307T3/en active Active
- 2008-04-17 AU AU2008240560A patent/AU2008240560B2/en not_active Ceased
- 2008-04-17 KR KR1020097021869A patent/KR101352416B1/en active IP Right Grant
- 2008-04-17 ES ES08736848.6T patent/ES2540566T3/en active Active
- 2008-04-17 HU HUE13190488A patent/HUE041656T2/en unknown
- 2008-04-17 CA CA2962519A patent/CA2962519C/en active Active
- 2008-04-17 CN CN2008800209043A patent/CN101679523B/en not_active Expired - Fee Related
- 2008-04-17 NZ NZ580194A patent/NZ580194A/en not_active IP Right Cessation
- 2008-04-17 SI SI200831444T patent/SI2164872T1/en unknown
- 2008-04-17 CA CA3059580A patent/CA3059580C/en active Active
- 2008-04-17 UA UAA200910613A patent/UA97516C2/en unknown
- 2008-04-17 EP EP08736848.6A patent/EP2164872B1/en active Active
- 2008-04-17 PL PL08736848T patent/PL2164872T3/en unknown
- 2008-04-17 LT LTEP13190488.0T patent/LT2692737T/en unknown
- 2008-04-17 RS RS20150427A patent/RS54066B1/en unknown
- 2008-04-17 EP EP13190488.0A patent/EP2692737B1/en active Active
- 2008-04-17 CA CA3059571A patent/CA3059571C/en active Active
- 2008-04-17 PT PT13190488T patent/PT2692737T/en unknown
- 2008-04-17 PL PL13190488T patent/PL2692737T3/en unknown
- 2008-04-18 US US12/081,707 patent/US7897149B2/en not_active Expired - Fee Related
-
2009
- 2009-10-15 ZA ZA200907220A patent/ZA200907220B/en unknown
- 2009-10-18 IL IL201601A patent/IL201601A/en active IP Right Grant
-
2010
- 2010-08-09 HK HK10107584.5A patent/HK1141039A1/en not_active IP Right Cessation
- 2010-11-05 US US12/940,476 patent/US8142783B2/en not_active Expired - Fee Related
-
2015
- 2015-06-08 HR HRP20150615TT patent/HRP20150615T1/en unknown
- 2015-06-23 CY CY20151100533T patent/CY1116413T1/en unknown
-
2018
- 2018-10-05 HR HRP20181616TT patent/HRP20181616T1/en unknown
- 2018-10-05 CY CY181101032T patent/CY1121132T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2019004I1 (en) | MODIFIED ANTI-IL-23P19 ANTIBODIES | |
FI20075278A0 (en) | Novel completely human anti-VAP-1 monoclonal antibodies | |
LTPA2018017I1 (en) | Human CGRP receptor binding antibodies | |
DK2131860T3 (en) | ANTI-sclerostin ANTIBODIES | |
SMT201700083B (en) | MONOCLONAL ANTIBODIES | |
BRPI0907532A2 (en) | Humanized anti-c5ar antibodies | |
BRPI0809677A2 (en) | Anti-GSE Antibodies | |
NO344963B1 (en) | Humanized antibody | |
DK2066695T3 (en) | ANTI-myostatin ANTIBODIES | |
BRPI0821777A2 (en) | Bivalent bispecific antibodies | |
BRPI0819165A2 (en) | Anti-vegf Antibodies | |
BRPI0923359A2 (en) | Anti-igf Antibodies | |
BRPI0906877A2 (en) | Improved anti-trkb antibodies | |
BRPI0814003A2 (en) | ANTIBODY FORMULATIONS | |
BRPI0814252A2 (en) | Antibody Formulations | |
BRPI0817273A2 (en) | Modified antibody constant region | |
BRPI0819210A2 (en) | Anti-rsv G Protein Antibodies | |
BRPI0907237A2 (en) | Anti-cldn6 antibody | |
ATE483732T1 (en) | MADCAM ANTIBODIES | |
DK2292663T3 (en) | Antagonistic human-light specific human monoclonal antibodies | |
BRPI0814111A2 (en) | CYTOTOXIC MONOCLONAL ANTIBODY | |
BRPI0815567A2 (en) | V-INTEGRINE ANTIALFA HYBRID ANTIBODIES DESIGNED | |
BRPI0807991A2 (en) | PREPARED ANTI-IL-23R ANTIBODIES. | |
IL200168A0 (en) | Monoclonal anti-cxcl13 antibodies | |
BRPI0817427A2 (en) | Anti-bst2 antibody |